血清SF、CA125、CA153联合检测在乳腺癌诊断中的临床价值

发布时间：2018-03-01 15:21

  本文关键词： 乳腺癌 SF CA125 CA153 诊断　出处：《河北医科大学》2015年硕士论文　论文类型：学位论文

【摘要】：目的:利用化学发光免疫分析法对乳腺癌患者血清SF(Serum ferritin,血清铁蛋白)、CA125(Carbohydrate antigen 125,糖类抗原125)和CA153(Carbohydrate antigen 153,糖类抗原153)进行检测,探讨其在乳腺癌诊断中的临床应用价值。材料与方法:1样本收集2013年12月至2014年12月邢台市人民医院肿瘤内科和肿瘤外科收治的乳腺癌患者156例,其中乳腺癌患者92例,乳腺良性疾病患者64例,所有乳腺癌癌患者均经组织病理学或细胞学确诊。另选择40例门诊健康体检者作为健康对照。对所有观察对象进行血清肿瘤标志物SF、CA125、CA153测定。2肿瘤标志物的测定SF、CA125和CA153均采用化学发光法测定。3数据的统计学分析采用SPSS17.0软件对数据进行统计学分析,数据资料呈正态分布,以均数±标准差(x±s)表示,组间比较采用t检验;定性资料组间的比较采用x2检验。检验水准α=0.05。结果:1血清SF、CA125和CA153在乳腺癌组、乳腺良性疾病组和健康体检组表达水平比较血清SF表达水平,乳腺癌组乳腺良性疾病组健康体检组,差异有统计学意义(P0.05)。血清CA125和CA153表达水平,乳腺癌组显著高于乳腺良性疾病组和健康体检组,差异有统计学意义(P0.05);乳腺良性疾病组和健康体检组比较,差异无统计学意义(P0.05)。2血清SF、CA125和CA153在不同分期乳腺癌表达水平比较血清SF表达水平:III期II期I期,差异有统计学意义(P0.05)。血清CA125、CA153表达水平:I期低于II期和III期,差异有统计学意义(P0.05);II期和III期比较,差异无统计学意义(P0.05)。三项肿瘤标志物血清表达水平均与乳腺癌分期呈正相关。3血清SF、CA125和CA153诊断价值评估(以乳腺良性疾病组作为对照)诊断乳腺癌的灵敏度:SFCA153CA125;特异度:CA153CA125SF。通过约登指数评估这三项肿瘤标志物的诊断价值,CA153最高,为0.5074;CA125最低,为0.2867。三项联合检查诊断乳腺癌的灵敏度达78.26%。结论:1 SF,CA125和CA153在乳腺癌的诊断中均有很好的应用价值,可作为乳腺癌的鉴定指标。2 SF,CA125和CA153均与乳腺癌分期呈正相关,血清水平越高提示着患者的病情越严重。3 SF诊断乳腺癌的灵敏度最高,CA153的特异性最好。综合评估,CA153诊断乳腺癌的价值最高,SF次之,CA125最差。三项联合检测能提高诊断乳腺癌的灵敏度。
[Abstract]:Objective: to detect serum SF(Serum ferritin, serum ferritin, carbohydrate antigen 125, carbohydrate antigen 125 and CA153(Carbohydrate antigen 153, carbohydrate antigen 153 in patients with breast cancer by chemiluminescence immunoassay. Materials and methods: from December 2013 to December 2014, 156 cases of breast cancer were collected from Department of Oncology and Cancer surgery, Xingtai people's Hospital, including 92 cases of breast cancer. 64 patients with benign breast disease, All patients with breast cancer were confirmed by histopathology or cytology. Another 40 outpatient healthy persons were selected as healthy controls. The serum tumor marker SFCA125CA153 was used to determine the tumor marker SFCA125. And CA153 were statistically analyzed by chemiluminescence. 3 data were analyzed by SPSS17.0 software. The data were normally distributed, expressed as mean 卤standard deviation (x 卤s), t test was used for comparison among groups, and x 2 test was used for comparison between qualitative data groups. The test level was 伪 0. 05. Results the serum SFCA125 and CA153 were in the breast cancer group. The expression level of serum SF was compared between benign breast disease group and healthy control group, and the difference was significant in breast cancer group and breast benign disease group (P 0.05). Serum CA125 and CA153 expression levels were significantly higher than those in breast benign disease group. The breast cancer group was significantly higher than the benign breast disease group and the healthy physical examination group, the difference was statistically significant (P 0.05). There was no significant difference in the expression of serum SF CA125 and CA153 in different stages of breast cancer. There was a significant difference in the level of serum SF expression between stage I and stage II of stage II, and there was a statistically significant difference in the level of expression of serum SF between stage 鈪，

本文编号：1552508